Table 1.
Clinicopathological characteristics in relation to APOBEC3G expression in patients with primary colon carcinoma and hepatic metastasis (n = 136)
| APOBEC3G expression in primary colon cancer | ||||
|
| ||||
| Factor | Positive | Negative | P value | |
|
| ||||
| Patients (n/%) | 89/65.4 | 47/34.6 | ||
| Age (years; mean ± SEM) | 66.3 ± 9.1 | 65.2 ± 8.9 | 0.725 | |
| Gender | Female (n) | 17 | 10 | 0.827 |
| Male (n) | 72 | 37 | ||
| Primary colon tumor location | Ascending colon (n) | 14 | 8 | 0.536 |
| Transverse colon (n) | 4 | 3 | ||
| Descending colon (n) | 71 | 36 | ||
| Primary colon tumor size | < 5 cm (n) | 55 | 30 | 0.681 |
| ≥ 5 cm (n) | 34 | 17 | ||
| Primary colon tumor histology grade | Low grade (n) | 43 | 21 | 0.877 |
| High grade (n) | 46 | 26 | ||
| Primary colon tumor differentiation | Well (n) | 14 | 12 | 0.633 |
| Moderate (n) | 68 | 32 | ||
| Poor (n) | 7 | 3 | ||
| Lymph node involvement | Yes (n) | 68 | 22 | 0.000 |
| No (n) | 21 | 25 | ||
| Vascular invasion | Yes (n) | 34 | 15 | 0.281 |
| No (n) | 55 | 32 | ||
| Serum CEA level | > 6 ng/mL (n) | 68 | 17 | 0.000 |
| ≤ 6 ng/mL (n) | 21 | 30 | ||
| HBV infection | Positive (n) | 8 | 9 | 0.752 |
| Negative (n) | 81 | 38 | ||
| HCV infection | Positive (n) | 2 | 3 | 0.878 |
| Negative (n) | 87 | 44 | ||
|
| ||||
| APOBEC3G expression in colon cancer hepatic metastasis | ||||
|
| ||||
| Factor | Positive | Negative | P value | |
|
| ||||
| Patients (n/%) | 91/66.9 | 45/33.1 | ||
| Age (years; mean ± SEM) | 67.3 ± 9.2 | 65.8 ± 9.3 | 0.885 | |
| Gender | Female (n) | 19 | 8 | 0.732 |
| Male (n) | 72 | 37 | ||
| Hepatic metastatic tumor number | Single (n) | 76 | 40 | 0.832 |
| Multiple (n) | 15 | 5 | ||
| Hepatic metastatic tumor size | < 5 cm (n) | 54 | 27 | 0.789 |
| ≥ 5 cm (n) | 37 | 18 | ||
| Hepatic metastatic histology grade | Low grade (n) | 46 | 17 | 0.875 |
| High grade (n) | 45 | 28 | ||
CEA, carcinoembryonic antigen. HBV, hepatitis C virus infection. HCV, hepatitis C virus infection.